Alimera Sciences, Inc.Alimera Sciences, Inc.Alimera Sciences, Inc.

Alimera Sciences, Inc.

No trades
See on Supercharts
Market capitalization
‪184.29 M‬USD
−2.16USD
‪−20.13 M‬USD
‪80.75 M‬USD
‪47.16 M‬
Beta (1Y)
1.65

About Alimera Sciences, Inc.

CEO
Richard S. Eiswirth
Headquarters
Alpharetta
Employees (FY)
159
Founded
2003
ISIN
US0162592028
FIGI
BBG000QLS2G2
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ALIM is 3.54 USD — it has increased by 0.57% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alimera Sciences, Inc. stocks are traded under the ticker ALIM.
Alimera Sciences, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Alimera Sciences, Inc. has a max estimate of 10.00 USD and a min estimate of 6.00 USD.
ALIM earnings for the last quarter are −1.32 USD whereas the estimation was 0.01 USD which accounts for ‪−26.50 K‬% surprise. Estimated earnings for the next quarter are 0.12 USD. See more details about Alimera Sciences, Inc. earnings.
Alimera Sciences, Inc. revenue for the last quarter amounts to ‪23.36 M‬ USD despite the estimated figure of ‪22.70 M‬ USD. In the next quarter revenue is expected to reach ‪24.33 M‬ USD.
Yes, you can track Alimera Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, ALIM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alimera Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ALIM reached its all-time high on Nov 24, 2010 with the price of 190.50 USD, and its all-time low was 0.0045 USD and was reached on Oct 31, 2019.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 159.00 employees. See our rating of the largest employees — is Alimera Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alimera Sciences, Inc. EBITDA is ‪7.28 M‬ USD, and current EBITDA margin is 9.01%. See more stats in Alimera Sciences, Inc. financial statements.